What is the intrinsic value of PCRX?
As of 2025-12-19, the Intrinsic Value of Pacira Biosciences Inc (PCRX) is
12.46 USD. This PCRX valuation is based on the model Peter Lynch Fair Value.
With the current market price of 25.88 USD, the upside of Pacira Biosciences Inc is
-51.86%.
Is PCRX undervalued or overvalued?
Based on its market price of 25.88 USD and our intrinsic valuation, Pacira Biosciences Inc (PCRX) is overvalued by 51.86%.
12.46 USD
Intrinsic Value
PCRX Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(125.70) - (29.15) |
(43.97) |
-269.9% |
| DCF (Growth 10y) |
(25.15) - (92.57) |
(35.57) |
-237.4% |
| DCF (EBITDA 5y) |
(10.77) - (11.35) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(11.64) - (11.28) |
(1,234.50) |
-123450.0% |
| Fair Value |
12.46 - 12.46 |
12.46 |
-51.86% |
| P/E |
11.47 - 18.52 |
13.82 |
-46.6% |
| EV/EBITDA |
19.37 - 29.57 |
23.51 |
-9.2% |
| EPV |
34.55 - 45.79 |
40.17 |
55.2% |
| DDM - Stable |
5.21 - 19.10 |
12.15 |
-53.0% |
| DDM - Multi |
(6.50) - (18.50) |
(9.61) |
-137.1% |
PCRX Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
1,113.36 |
| Beta |
0.81 |
| Outstanding shares (mil) |
43.02 |
| Enterprise Value (mil) |
1,342.49 |
| Market risk premium |
4.60% |
| Cost of Equity |
8.52% |
| Cost of Debt |
4.67% |
| WACC |
6.62% |